Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis
Value in Health · 2023-07 · 26 (7) · 984-994
DOI: 10.1016/j.jval.2023.02.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023-07. Verfasst von Amanda W Erbe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management and Health Economics, University of Oslo, Oslo, Norway. Electronic address: amanda.w.erbe@gmail.com. Hauptthemen laut MEDLINE: Hemodialysis, Home, Kidney Failure, Chronic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fresenius Medical Care North America.
Abstract (Originalsprache)
OBJECTIVES: This study aimed to determine the lifetime cost-effectiveness of increasing home hemodialysis as a treatment option for patients experiencing peritoneal dialysis technique failure compared with the current standard of care. METHODS: A Markov model was developed to assess the lifetime costs, quality-adjusted life-years, and cost-effectiveness of increasing the usage an integrated home dialysis model compared with the current patient pathways in the United Kingdom. A secondary analysis was conducted including only the cost difference in treatments, minimizing the impact of the high cost of dialysis during life-years gained. Sensitivity and scenario analyses were performed, including analyses from a societal rather than a National Health Service perspective. RESULTS: The base-case probabilistic analysis was associated with incremental costs of £3413 and a quality-adjusted life-year of 0.09, resulting in an incremental cost-effectiveness ratio of £36 341. The secondary analysis found the integrated home dialysis model to be dominant. Conclusions on cost-effectiveness did not change under the societal perspective in either analysis. CONCLUSIONS: The base-case analysis found that an integrated home dialysis model compared with current patient pathways is likely not cost-effective. These results were primarily driven by the high baseline costs of dialysis during life-years gained by patients receiving home hemodialysis. When excluding baseline dialysis-related treatment costs, the integrated home dialysis model was dominant. New strategies in kidney care patient pathway management should be explored because, under the assumption that dialysis should be funded, the results provide cost-effectiveness evidence for an integrated home dialysis model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Management and Health Economics, University of Oslo, Oslo, Norway. Electronic address: amanda.w.erbe@gmail.com.
- Market Access & Health Economics, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany. Electronic address: Dana.kendzia@fmc-ag.com.
- Market Access & Health Economics, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany.
- Health Economics, Market Access & Product Management, Fresenius Medical Care (UK) Ltd, Huthwaite, England, UK.
- Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
Förderung
- Fresenius Medical Care North America
Zitieren
APA
Erbe, A. W., Kendzia, D., Busink, E., Carroll, S., & Aas, E. (2023). Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis. Value in Health, 26(7), 984-994. https://doi.org/10.1016/j.jval.2023.02.009
Vancouver
Erbe AW, Kendzia D, Busink E, Carroll S, Aas E. Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis. Value in Health. 2023;26(7):984-994. doi:10.1016/j.jval.2023.02.009
BibTeX
@article{Erbe2023,
author = {Erbe, Amanda W and Kendzia, Dana and Busink, Ellen and Carroll, Suzanne and Aas, Eline},
title = {Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis},
journal = {Value in Health},
year = {2023},
volume = {26},
number = {7},
pages = {984--994},
doi = {10.1016/j.jval.2023.02.009}
}
EUVIMED